The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
 
Manabu Muto
Speakers' Bureau - Canon Medical System; Chugai Pharma; Daiichi Sankyo/Lilly; Illumina; Incyte Japan; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Shionogi
Research Funding - Canon Medical System; Chugai Pharma; H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical
 
Motoo Nomura
Honoraria - Bristol-MyersSquibbK.K.; MSD; ONOPHARMACEUTICALCO.,LTD.
Consulting or Advisory Role - ONOPHARMACEUTICALCO.,LTD.
 
Katsuyuki Sakanaka
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - MSD
 
Juko Shimizu
No Relationships to Disclose
 
Shinya Ohashi
No Relationships to Disclose
 
Akinori Watanabe
No Relationships to Disclose
 
Chikatoshi Katada
No Relationships to Disclose
 
Yusuke Amanuma
No Relationships to Disclose
 
Keiko Minashi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); BeiGene (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Kojima
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; EA Pharma; Japan Esophageal Society; Japanese Society of Pharmaceutical Health Care and Sciences; Kyowa Kirin International; Liang Yi Hui Healthcare; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; CMIC; NPT Co.,Ltd.
Research Funding - Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kengo Nagashima
Consulting or Advisory Role - Kowa; Lilly (Inst); Senju Pharmaceutical; Toray Industries
 
Ihhwa Kim
No Relationships to Disclose
 
Harue Tada
No Relationships to Disclose
 
Akiyoshi Nakakura
No Relationships to Disclose
 
Hiroki Sasaki
No Relationships to Disclose